Johnson & Johnson (NYSE:JNJ) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Johnson & Johnson has a consensus analyst rating of “Moderate Buy”, with 20 buy ratings and 7 holds across 27 covering firms. The average 12-month price target is about $253.04.
• Several analysts recently raised price targets or reiterated bullish views on JNJ, including HSBC, Argus, Morgan Stanley, TD Cowen, and Johnson Rice. Recent targets range from $250 to $283, reflecting continued optimism around the stock.
• The company has posted solid fundamentals, including Q1 earnings and revenue beats and a recently increased quarterly dividend to $1.34 per share. The article also highlights positive catalysts such as encouraging Erleada trial data and a planned $1 billion+ investment in a Florida manufacturing facility.

Johnson & Johnson (NYSE:JNJ - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty-seven ratings firms that are covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $253.0435.

A number of brokerages recently issued reports on JNJ. HSBC lifted their price target on shares of Johnson & Johnson from $265.00 to $280.00 and gave the stock a "buy" rating in a research note on Tuesday, March 17th. Argus boosted their price objective on shares of Johnson & Johnson from $240.00 to $275.00 and gave the stock a "buy" rating in a research report on Thursday, April 16th. Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. TD Cowen initiated coverage on shares of Johnson & Johnson in a research report on Wednesday, April 8th. They set a "buy" rating and a $250.00 price objective for the company. Finally, Johnson Rice upgraded shares of Johnson & Johnson from a "hold" rating to an "outperform" rating in a research report on Wednesday, May 13th.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company's stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors have recently modified their holdings of JNJ. Auto Owners Insurance Co increased its holdings in shares of Johnson & Johnson by 22,225.6% in the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares during the period. Norges Bank purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth $6,924,523,000. Capital World Investors purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth $2,005,942,000. Diamant Asset Management Inc. boosted its position in shares of Johnson & Johnson by 24,436.5% during the 1st quarter. Diamant Asset Management Inc. now owns 4,473,008 shares of the company's stock worth $109,338,000 after purchasing an additional 4,454,778 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock worth $49,740,362,000 after buying an additional 3,731,074 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s prostate cancer drug Erleada showed encouraging clinical results, with Reuters-reported data indicating it cut the risk of cancer spread or death by 20% in a study setting. That kind of pipeline progress can support longer-term revenue growth. Article Title
• Positive Sentiment: The company continues to be highlighted as a strong dividend stock, with articles pointing to Johnson & Johnson’s long history of dividend increases and its appeal to income-focused investors seeking stability in a volatile market. Article Title
• Positive Sentiment: Johnson & Johnson announced plans to invest more than $1 billion in a Florida contact lens manufacturing facility, reinforcing confidence in future operating capacity and U.S. production investment. Article Title
• Neutral Sentiment: Several commentary pieces describe JNJ as a defensive name that may hold up better if markets weaken, but these articles are largely opinion-based and do not add new fundamental catalysts. Article Title
• Negative Sentiment: Shares have been soft over the past few months, with one note saying the stock is down about 3% in three months despite solid results and pipeline progress. That recent weakness may be weighing on sentiment even as investors debate whether the dip is attractive. Article Title

Johnson & Johnson Price Performance

Shares of JNJ opened at $228.37 on Friday. Johnson & Johnson has a 1-year low of $149.04 and a 1-year high of $251.71. The stock has a market cap of $549.73 billion, a PE ratio of 26.40, a P/E/G ratio of 2.24 and a beta of 0.26. The firm has a 50-day simple moving average of $230.61 and a two-hundred day simple moving average of $228.09. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The business had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. During the same period last year, the business earned $2.77 earnings per share. The business's revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th were given a dividend of $1.34 per share. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 annualized dividend and a dividend yield of 2.3%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's payout ratio is presently 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.